Related Experiment Video
Updated: May 11, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Copeptin concentrations are not elevated in gestational diabetes mellitus
Mahmut Oncul1, Abdullah Tuten, Mine Kucur
1Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Archives of Gynecology and Obstetrics
|May 17, 2013
Summary
Serum copeptin levels did not differ between women with gestational diabetes mellitus (GDM) and healthy pregnancies. However, copeptin correlated with insulin resistance in GDM patients, suggesting a potential link for future research.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Metabolic Disorders
Background:
- Gestational diabetes mellitus (GDM) is a common pregnancy complication.
- Copeptin, a marker of arginine vasopressin, has been implicated in metabolic regulation.
Purpose of the Study:
- To compare serum copeptin levels in women with GDM versus those with uncomplicated pregnancies.
- To explore the relationship between copeptin, insulin resistance, and GDM.
Main Methods:
- A case-control study involving 45 women with GDM and 40 controls.
- Maternal serum copeptin levels measured by enzyme-linked immunosorbent assay (ELISA).
- Insulin resistance assessed using HOMA-IR (Homeostatic Model Assessment for Insulin Resistance).
Main Results:
- No significant difference in copeptin levels between GDM and control groups (p=0.24).
- Significantly higher HOMA-IR and insulin levels observed in women with GDM (p=0.002 and p=0.004, respectively).
- Copeptin concentrations showed a significant positive correlation with insulin levels (r=0.329, p=0.002) and HOMA-IR (r=0.289, p=0.007).
Conclusions:
- Serum copeptin levels do not distinguish between GDM and non-GDM pregnancies.
- A significant correlation exists between copeptin and markers of insulin resistance (HOMA-IR) in GDM.
- Larger studies are warranted to elucidate the role of copeptin in GDM pathophysiology.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...